// App-Quantinova.ai

1489 : Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials

Researchers

Presenter

  • Philipp D. le Coutre

Principal Investigators

  • Timothy P. Hughes

  • Francois-Xavier Mahon

  • Dong-Wook Kim

  • Juan Luis Steegmann

  • Neil P. Shah

  • Nicola Wallis

  • Jorge Cortes

Medical Centers

  • Charite, Campus Virchow Medizinische Klinik m.S. Hamatologie und Onkologie, Universitatsmedizin Berlin, Berlin, Germany

  • Centre Hospitalier Universitaire de Bordeaux, Laboratoire -Hematologie et Service des Maladies du Sang, Bordeaux et Institut Bergonie, Bordeaux, France

  • University of California, San Francisco, CA

  • Department of Haematology, Centre for Cancer Biology, Adelaide, Australia

  • Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • Germany

  • Spain

  • Australia

  • United States

  • France

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Pulmonary arterial hypertension

  • Acute lymphoblastic leukemia

  • Peripheral artery disease

  • Chronic Myelogenous Leukemia

  • Tricuspid regurgitation

  • Coronary Artery Disease

  • Diabetes

  • Dyslipidemia

  • Congestive heart failure

  • Hypertension

  • Obesity

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Albyl-E

  • Erythropoietin

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved